Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To assess the safety and tolerability of two dose levels of a new insulin glargine
formulation in a once-daily multiple dosing regimen
Secondary Objective:
To compare the pharmacokinetic and pharmacodynamic properties of two dose levels of a new
insulin glargine formulation with 0.4 U/kg Lantus® in a once-daily multiple dosing regimen